Research output per year
Research output per year
Personal profile
Personal profile
Dr. Li finished his medical school at Beijing Medical University and his graduate school at Penn State. He had his postdoctoral training at Stanford University before joining the Research Institute in late 2017.
Research interests
Dr. Li's research interest includes 1) non-genetic mechanisms of therapeutic resistance, and 2) rational combination therapy. Dr. Li's lab utilizes both experimental and computational approaches to study cancer biology and therapeutics.
External positions
Associate Professor of Cancer Biology in Medicine, Weill Cornell Medicine
Apr 1 2018 → …
Divisions
- Medical Oncology
Cancer Research Programs
- Cancer Biology and Immunology
Fingerprint
Dive into the research topics where Yulin Li is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Chemotherapy-induced activation of caspase-1 and IL-1α release by cancer cells remotely skews myelopoiesis to drive pro tumorigenic systemic neutrophil-dominant inflammation
Wong, S. Q., Hayashi, K., Subel, E. J., Huang, Y. H., Gao, H., Garcia, H. E., Porter, S. J., Karabicici, M., Hoi, X. P., Alonzo, M. D., Kasabyan, A., Tsouko, E., Shin, C. S., Bouchier-Hayes, L., Korentzelos, D., Chen, C., Brooks, M., Yin, Z., Titus, R. S. & Zhou, L. & 8 others, , Apr 20 2026, In: Nature Communications. 17, 1Research output: Contribution to journal › Article › peer-review
Open Access3 Link opens in a new tab Scopus citations -
Abstract P3-02-28: A combination approach to target residual tumors via ferroptosis induction
Wang, Z., Hassanain, H., Azizian, N. G., Sullivan, D. K., Chang, J. C., Pegram, M. & Li, Y., Jun 13 2025, (Unpublished).Research output: Contribution to conference › Abstract
-
Nuclear to cytoplasmic transport is a druggable dependency in MYC-driven hepatocellular carcinoma
Deutzmann, A., Sullivan, D. K., Dhanasekaran, R., Li, W., Chen, X., Tong, L., Mahauad-Fernandez, W. D., Bell, J., Mosley, A., Koehler, A. N., Li, Y. & Felsher, D. W., Feb 1 2024, In: Nature Communications. 15, 1, p. 963 963.Research output: Contribution to journal › Article › peer-review
Open Access15 Link opens in a new tab Scopus citations -
mTOR inhibition attenuates chemosensitivity through the induction of chemotherapy resistant persisters
Liu, Y., Azizian, N. G., Sullivan, D. K. & Li, Y., Dec 2022, In: Nature Communications. 13, 1, 7047.Research output: Contribution to journal › Article › peer-review
Open Access60 Link opens in a new tab Scopus citations -
mTOR inhibition attenuates chemosensitivity through the induction of chemotherapy resistant persisters
Liu, Y., Azizian, N. G., Sullivan, D. K. & Li, Y., Nov 17 2022, In: Nature Communications. 7047.Research output: Contribution to journal › Article › peer-review
Open Access
Prizes
-
American Cancer Society Research Scholar Award
Li, Y. (Recipient), Oct 6 2024
Prize: Prize (including medals and awards)
-
American Cancer Society Research Scholar Award
Li, Y. (Recipient), Oct 1 2023
Prize: Prize (including medals and awards)
-
Houston Methodist Neal Cancer Center Innovation Award
Li, Y. (Recipient), Aug 22 2023
Prize: Prize (including medals and awards)
-
Houston Methodist Neal Cancer Center Innovation Award
Li, Y. (Recipient), Aug 25 2024
Prize: Prize (including medals and awards)
-
Presidential Award - Career Cornerstone
Li, Y. (Recipient), Jun 13 2024
Prize: Prize (including medals and awards)